Biotech Ingredients - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The biotech ingredients market size is projected to expand from USD 2.45 billion in 2025 and USD 2.63 billion in 2026 to USD 3.87 billion by 2031, registering a CAGR of 8.03% between 2026 to 2031. This report is Segmented by Source (Microbial, and More), Ingredient Type (Enzymes, and More), Application (Pharmaceuticals, and More), Technology (Fermentation, and More), Form (Liquid, Powder, Granule, Pellet), Process (Upstream Processing, and More), End User (Pharmaceutical Companies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Biotech Ingredients Market Trends and Insights

Expansion of Precision Fermentation Platforms for High-Value Functional Ingredients

The biotech ingredients market is seeing precision fermentation replace conventional extraction in a growing number of high-value molecules. Engineered microbial hosts are now being used to produce hyaluronic acid, squalane, recombinant collagen, and resveratrol at commercially relevant yields. Research published in Applied Sciences in 2025 showed that engineered Bacillus subtilis strains delivered hyaluronic acid yields above 7 g/L in 11 hours, which cut fermentation time sharply versus conventional Streptococcus processes while also improving purity and reducing purification burden. The same production shift is improving cost competitiveness, as fermentation-derived squalane is priced below olive-derived alternatives, making supply substitution easier for personal care formulators without forcing product redesign. The OECD also noted in 2025 that AI and machine learning are reducing development time by as much as 70%, which is improving the economics of fast-cycle molecule development and favoring early platform leaders in the biotech ingredients market.

Rising Shift Toward Bio-Based Formulation Substitution in Cosmetics and Personal Care

The biotech ingredients market is gaining support from personal care brands that are replacing conventional inputs with bio-based alternatives. Consumer sustainability preferences in Europe have become strong enough to shape active reformulation programs at major cosmetics companies, which is pushing ingredient suppliers toward biotechnology-backed solutions. Evonik showed this direction clearly at in-cosmetics Global 2025, where it highlighted biotechnology-based biosurfactants, biopolymers, vegan collagen, and ceramides, and reported a climate footprint reduction above 60% for selected enzymatically produced emollients compared with chemical process alternatives. BASF also expanded its Isobionics portfolio in March 2025 with two fermentation-derived flavor ingredients that offer consistent purity and more reliable supply than agricultural extraction routes. In the biotech ingredients market, this move is not only about sustainability, because brands also want steadier quality, fewer seasonal disruptions, and better traceability under tighter compliance frameworks in premium beauty and personal care channels.

High Scale-Up Failure Risk Between Lab, Pilot, and Commercial Fermentation

The biotech ingredients market still faces a major hurdle when laboratory performance must be reproduced in pilot and commercial systems. The OECD described this transition as a persistent structural bottleneck in synthetic biology, affecting both early-stage companies and larger producers. Oxygen transfer, shear stress, pH behavior, and nutrient distribution change in larger bioreactors, which often makes laboratory benchmarks unreliable at full scale. Genetic instability adds another problem, because engineered strains can lose or silence target traits during longer commercial runs, which reduces yields and raises batch failure risk. The pressure is greater for smaller companies in the biotech ingredients market, because repeated scale-up setbacks consume cash, extend launch timelines, and require engineering capabilities that are usually stronger at incumbent manufacturers.

Other drivers and restraints analyzed in the detailed report include:

• Biomanufacturing Capacity Buildout for Non-Pharma Ingredient Supply Security
• Rising Demand for Biotech-Derived Therapeutic and Nutritional Ingredients in High-Value Health Segments
• Downstream Purification Complexity for Multi-Compound Ingredient Streams

Segment Analysis

Microbial ingredients accounted for 61.31% of the biotech ingredients market size in 2025, which reflected long-standing industrial investment in yeast, bacterial, and fungal production hosts across enzymes, amino acids, vitamins, and organic acids. This scale advantage came from decades of fermentation learning, established production infrastructure, and broad regulatory familiarity across end-use sectors. In the biotech ingredients market, microbial sourcing remains the most commercially proven route for high-volume output because it combines flexibility with reliable economics across many standardized ingredient categories. The segment also benefits from compatibility with both commodity and specialty product pipelines, which gives producers room to allocate capacity based on changing demand profiles.

Novonesis remains a major anchor in this segment after the merger of Novozymes and Chr. Hansen, and its production network widened further with the Rayong facility acquisition in 2026. Plant-based sourcing still holds a differentiated position in biotech ingredients tied to alkaloids, terpenoids, and glycosides where traceable natural origin matters to buyers and can support premium pricing. Animal-based sourcing is the fastest-growing source segment, with the biotech ingredients market size for this segment expected to expand at 8.68% CAGR between 2026 and 2031. That growth is increasingly tied to recombinant collagen, lactoferrin, and other animal-identical proteins produced through microbial fermentation rather than conventional animal extraction, which changes the meaning of the category without changing the functional value that customers want.

Enzymes held the largest ingredient-type share at 29.68% in 2025, which kept them at the center of the biotech ingredients market because they remain essential in detergents, food processing, pharmaceutical production, and industrial biotechnology. Their position is supported by repeat-use demand, well-established customer qualification cycles, and strong compatibility with microbial production platforms. In the biotech ingredients market, enzymes also benefit from a wide spread of applications, which reduces dependence on any one downstream customer group. That base makes the category stable even as newer bioactive segments attract more attention and capital.

Proteins and peptides are projected to grow at 10.12% through 2031, making them the fastest-growing ingredient category in the biotech ingredients market. This growth reflects rising commercial use in medical beauty, infant and clinical nutrition, diagnostics, and premium performance nutrition. Dyadic International’s AlbuFree DX launch showed how recombinant albumin is moving historically familiar molecules into higher-value, animal-free, specification-driven use cases. BASF and IFF also expanded work on next-generation enzyme systems in 2025, which showed that established players are still investing in foundational categories even while higher-growth protein platforms gain share. Amino acids remain important as the second-largest category, while vitamins, organic acids, polysaccharides, terpenoids, alkaloids, and glycosides continue to diversify demand across flavors, fragrances, agriculture, and nutraceutical channels. Collagen and gelatin are in transition, because conventional animal-derived volumes remain relevant in food and pharmaceuticals, but recombinant and fermentation-derived collagen is expanding in high-value cosmetic and medical use cases where purity and consistency matter more.

Pharmaceuticals represented 39.16% of the biotech ingredients market share in 2025, which kept them as the largest application segment. This leadership reflects deep dependence on fermentation-derived APIs, excipients, biologic precursors, and tightly specified processing inputs. The biotech ingredients market continues to draw support from pharmaceutical demand because this segment values reproducibility, purity, and supply assurance, all of which reward suppliers with strong process control. AbbVie’s 2026 decision to invest USD 380 million in new API manufacturing capacity showed that major drug producers are still expanding biotechnology-enabled production systems at scale.

Plant nutrition and health care is projected to grow at 9.34% through 2031, making it the fastest-growing application in the biotech ingredients market. Growth in this segment is supported by demand for biopesticides, biostimulants, and soil-active biological inputs that can deliver targeted performance under tighter residue and sustainability requirements. Food and beverages remain an important demand channel for enzymes, amino acids, vitamins, and fermentation-derived aroma compounds, even as price competition remains visible in some standardized categories. Personal care and cosmetics are expanding on the back of biotechnology-based bioactives, with Evonik and Symrise both showing how bio-derived formulations are moving deeper into premium beauty pipelines. Animal nutrition and health care, along with medical beauty, are smaller segments by volume, yet they remain strategically important because they absorb differentiated molecules with stronger pricing power and more specialized performance claims.

Complete Report Scope:

• By Source
  • Microbial
  • Plant-Based
  • Animal-Based
• By Ingredient Type
  • Enzymes
  • Amino Acids
  • Organic Acids
  • Proteins and Peptides
  • Collagen and Gelatin
  • Vitamins
  • Terpenoids
  • Alkaloids
  • Glycosides
  • Polysaccharides
• By Application
  • Pharmaceuticals
  • Food and Beverages
  • Personal Care and Cosmetics
  • Plant Nutrition and Health Care
  • Animal Nutrition and Health Care
  • Medical Beauty
• By Technology
  • Fermentation
  • Biocatalysis
  • Cell Culture
  • Genetic Engineering
  • Synthetic Biology
  • Metabolic Engineering
• By Form
  • Liquid
  • Powder
  • Granule
  • Pellet
• By Process
  • Upstream Processing
  • Downstream Processing
  • Formulation
  • Purification
• By End User
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Institutes
  • Contract Research Organizations
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.64% of the biotech ingredients market share in 2025, which kept it as the largest regional market. This position rests on strong pharmaceutical biomanufacturing capacity, established fermentation infrastructure, and an innovation ecosystem that still supports commercialization of new biotech-derived actives. AbbVie’s USD 380 million investment in new API manufacturing facilities in Q1 2026 showed that large-scale capacity expansion is still active in the region. North America also benefits from a dense base of ingredient developers, specialty manufacturers, and platform technology companies that can support scale-up, qualification, and downstream application work. In the biotech ingredients market, this combination of production depth and financing capacity continues to favor North America in high-value therapeutic, nutritional, and industrial ingredient categories.

Asia-Pacific is projected to grow at 9.96% through 2031, making it the fastest-growing region in the biotech ingredients market. Growth is being supported by capacity expansion in China, India’s contract biotechnology manufacturing base, and new facility investment across Southeast Asia. Novonesis’ Rayong acquisition in Thailand is a clear example of how suppliers are positioning for regional feedstock access, lower operating costs, and faster delivery into local demand centers. Japan and South Korea add strength in high-value amino acid, vitamin, and personal care bioactive development, which supports regional depth beyond volume manufacturing.

Europe remains a major center in the biotech ingredients market because it combines industrial biotechnology capability with strong customer demand for traceable and sustainability-backed inputs. Evonik, BASF, and related suppliers continue to anchor enzyme, amino acid, and personal care ingredient supply across the region. Givaudan’s White Biotechnology Innovation Centre in Toulouse strengthened France’s position in advanced fragrance and beauty bioactives. South America is increasingly relevant as a production base, with Amyris expanding precision fermentation capacity in Brazil on the back of feedstock and cost advantages. The Middle East and Africa remain at an earlier stage, yet demand is rising in food security, nutraceutical, and pharmaceutical inputs, even though the region still depends more on imports than local production.

List of Companies Covered in this Report:

• Abbvie
• Advanced Biotech
• Amyris, Inc.
• BASF
• Biocon
• Conagen, Inc.
• Debut Biotechnology, Inc.
• dsm-firmenich
• Evonik Industries
• Fermenta Biotech Limited
• Firmenich International SA
• Givaudan
• International Flavors and Fragrances Inc.
• Merck
• Novozymes A/S
• Robertet Group
• Sensient Technologies
• Symrise
• Titan Biotech

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support